Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC Reply

被引：0
|
作者：
Cho, Byoung C. [1 ]
Sethi, Seema [2 ]
Spira, Alexander I. [3 ]
机构：
[1] Yonsei Univ, Coll Med, Seoul, South Korea
[2] Janssen Res & Dev, Spring House, PA USA
[3] Virginia Canc Specialists, Fairfax, VA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2025年 / 392卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：620 / 621
页数：2
相关论文
共 50 条
  • [31] EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
    Liu, Ao
    Wang, Xiaoming
    Wang, Lian
    Zhuang, Han
    Xiong, Liubo
    Gan, Xiao
    Wang, Qian
    Tao, Guanyu
    BMC CANCER, 2024, 24 (01)
  • [32] RELAY: final overall survival with erlotinib plus ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC (mNSCLC)
    Nakagawa, K.
    Garon, E. B.
    Nishio, M.
    Seto, T.
    Nishio, K.
    Kasahara, K.
    Nishino, K.
    Satouchi, M.
    Yoh, K.
    Hayashi, H.
    Enatsu, S.
    Frimodt-Moller, B.
    Matsui, T.
    Varughese, S. C.
    Visseren-Grul, C.
    Reck, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1313 - S1313
  • [33] Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
    Nishio, Kazuto
    Seto, Takashi
    Nishio, Makoto
    Reck, Martin
    Garon, Edward B.
    Sakai, Kazuko
    Goto, Koichi
    Kato, Terufumi
    Nakanishi, Yoichi
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Kiura, Katsuyuki
    Ohe, Yuichiro
    Tamura, Tomohide
    Visseren-Grul, Carla
    Frimodt-Moller, Bente
    Hozak, Rebecca R.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [34] Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1341 - 1342
  • [35] Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
    van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk
    Badrising, Sushil K.
    Burgers, Sjaak
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (05): : 478 - 479
  • [36] Gefitinib Approved for EGFR-Mutated NSCLC
    不详
    CANCER DISCOVERY, 2015, 5 (09) : 896 - 896
  • [37] Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
    Zhou, Qing
    Xu, Chong-Rui
    Cheng, Ying
    Liu, Yun-Peng
    Chen, Gong-Yan
    Cui, Jiu-Wei
    Yang, Nong
    Song, Yong
    Li, Xiao-Ling
    Lu, Shun
    Zhou, Jian-Ying
    Ma, Zhi-Yong
    Yu, Shi-Ying
    Huang, Cheng
    Shu, Yong-Qian
    Wang, Zhen
    Yang, Jin-Ji
    Tu, Hai-Yan
    Zhong, Wen-Zhao
    Wu, Yi-Long
    CANCER CELL, 2021, 39 (09) : 1279 - +
  • [38] Simulation in the Management of EGFR-Mutated Advanced NSCLC: Seeing Beyond Age
    Carey, Christine
    Herrmann, Tara
    Warters, Martin
    Blevins, Douglas
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S270 - S270
  • [39] Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC
    Jiang, S.
    Hurry, M.
    Hueniken, K.
    Brown, M. C.
    Liang, M.
    Patel, D.
    Labbe, C.
    Eng, L.
    Naik, H.
    Bradbury, P.
    Leighl, N.
    Shepherd, F.
    Xu, W.
    Liu, G.
    Walton, R.
    O'Kane, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S420 - S421
  • [40] Amivantamab and lazertinib in treatment-naive EGFR-mutated advanced non-small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
    Lee, Se-Hoon
    Cho, Byoung Chul
    Han, Ji-Youn
    Cho, Eun Kyung
    Lee, Jong-Seok
    Lee, Ki Hyeong
    Curtin, Joshua C.
    Gao, Grace
    Xie, John
    Schnepp, Robert W.
    Bauml, Joshua Michael
    Knoblauch, Roland E.
    Thayu, Meena
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345